University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3P-12-1

Phase IB Multi-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Anti-Neoplastic Activity of Gemcitabine Administered in Combination with Continuous Intravenous Doses of PRI-724, a CBP/ß-Catenin Inhibitor, to Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy with FOLFIRINOX (or FOLFOX).

Type: Treatment
Phase: Phase I/II
Status: Closed to Accrual with Ongoing Follow-up
Treatments: Chemotherapy: Systemic
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Ramona Lujan, R.N., Raluca Agafitei, Coordinator, Arthur Alvarez, D.M., Arthur Alvarez, D.M., Judy Lam-Tran, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.